Gimv et al. invest €5.5m in pharma company Multiplicom

Other investors included Flemish investment company PMV, RMM (Rudi Marien), Belgian inter-university venture capital fund Qbic, and Flanders-based life sciences research institute VIB. 

Gimv, VIB and Biotech Fonds Flanderen, which is managed my Gimv, invested €2m in Multiplicom in April 2011.

Company
Multiplicom is a Belgian biotechnology company that produces molecular diagnostic kits for laboratory testing of personalised medicine. It sells kits for bowel cancer, heart failure and cystic fibrosis, as well as kidney and muscle disease.

The company was founded in 2010, when it span out of the University of Antwerp and VIB.

People
Health and care associate Christophe van Vaeck led the investment for Gimv. Life sciences investment manager Bram Vanparys represented PMV, while managing partner Marc Zabeau represented Qbic. Dirk Pollet is CEO of Multiplicom. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Expansion
• Gimv
• Belgium